Although first- and second-generation EGFR-TKIs benefit patients with NSCLC who carry activating EGFR mutations, acquired resistance always occurs within a median of 10–14 months under EGFR-TKI therapy [4,7,8]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.